SCHEMBL14733488

SCHEMBL14733488

N#Cc1nc2ccc3ncnc(Nc4ccc5c(c4)OCO5)c3c2s1

nearest known ligand 0.68

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
DYRK1A Q13627 16/20 0.68
DYRK1B Q9Y463 8/20 0.66
GSK3A P49840 1/20 0.66
GSK3B P49841 1/20 0.66
PIK3CA P42336 1/20 0.47
PIK3CG P48736 1/20 0.47
CLK1 P49759 1/20 0.47
KDM4E B2RXH2 1/20 0.43
USP2 O75604 1/20 0.43
CYP1A2 P05177 1/20 0.43
CYP3A4 P08684 1/20 0.43
CYP2D6 P10635 1/20 0.43
MAPT P10636 1/20 0.43
CYP2C9 P11712 1/20 0.43
TSHR P16473 1/20 0.43
MAPK1 P28482 1/20 0.43
HSD17B10 Q99714 1/20 0.43
RAF1 P04049 1/20 0.43
BRAF P15056 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14733456 0.94 DYRK1A (0.66) DYRK1ADYRK1BGSK3AGSK3BPIK3CA
SCHEMBL14733420 0.85 DYRK1A (0.67) DYRK1ADYRK1BGSK3AGSK3B
SCHEMBL17060586 0.82 DYRK1A (0.84) DYRK1ADYRK1BGSK3AGSK3B
SCHEMBL17060624 0.81 DYRK1A (1.00) DYRK1ADYRK1BGSK3AGSK3B
SCHEMBL14733551 0.81 DYRK1A (1.00) DYRK1ADYRK1BGSK3AGSK3B
SCHEMBL14733458 0.81 DYRK1A (0.47) DYRK1ADYRK1BGSK3AGSK3B
SCHEMBL14733493 0.81 DYRK1A (0.63) DYRK1ADYRK1BGSK3AGSK3BCLK1
SCHEMBL14733542 0.80 DYRK1A (0.68) DYRK1ADYRK1BGSK3AGSK3B
SCHEMBL14733564 0.79 DYRK1A (1.00) DYRK1ADYRK1BGSK3AGSK3B
SCHEMBL14733533 0.79 DYRK1A (1.00) DYRK1ADYRK1BGSK3AGSK3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9446044-B2 DYRK1 inhibitors and uses thereof DIAXONHIT (FR) 2016-09-20 US disclosed
US-9446044-B2 DYRK1 inhibitors and uses thereof DIAXONHIT (FR) 2016-09-20 US disclosed
EP-2744797-B1 DYRK1 INHIBITORS AND USES THEREOF DIAXONHIT (FR) 2015-09-09 EP disclosed
EP-2744797-B1 DYRK1 INHIBITORS AND USES THEREOF DIAXONHIT (FR) 2015-09-09 EP disclosed
US-20140275064-A1 DYRK1 INHIBITORS AND USES THEREOF DIAXONHIT (FR) 2014-09-18 US disclosed
US-20140275064-A1 DYRK1 INHIBITORS AND USES THEREOF DIAXONHIT (FR) 2014-09-18 US disclosed
WO-2013026806-A1 DYRK1 INHIBITORS AND USES THEREOF EXONHIT SA (FR) 2013-02-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140275064-A1 DYRK1 INHIBITORS AND USES THEREOF DYRK1A, DYRK1B, DYRK2 DYRK1A 1/4885DYRK1B 2/4885GSK3A 204/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.